Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.43 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.43 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.43 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.42 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.42 |
| ▸ | MGMT | P16455 | 4/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | TPO | P07202 | 1/20 | 0.44 |
| ▸ | EPX | P11678 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595507 | 0.98 | MGMT (0.48) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL30026947 | 0.98 | MGMT (0.48) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL30271317 | 0.87 | L3MBTL1 (0.46) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6175355 | 0.87 | L3MBTL1 (0.46) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL26329102 | 0.85 | CYP1A2 (0.46) | NUDT1L3MBTL1CYP3A4TSHRLMNA | |
| SCHEMBL29210862 | 0.83 | NUDT1 (0.41) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL29424833 | 0.83 | LTA4H (0.49) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL2191517 | 0.83 | LTA4H (0.49) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL23274021 | 0.80 | NUDT1 (0.49) | NUDT1L3MBTL1TSHRGAAMAPT | |
| SCHEMBL30579734 | 0.79 | GRM5 (0.40) | MGMTCDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720068-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | Beone Medicines I GmbH (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-20260077051-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEONE MEDICINES I GMBH (CH) | 2026-03-19 | — | — | US | disclosed |
| WO-2024245430-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2024-12-05 | — | — | WO | disclosed |
| US-20240165243-A1 | EGFR DEGRADERS AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-05-23 | — | — | US | disclosed |
| US-20240131167-A1 | EGFR Degraders and Associated Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-04-25 | — | — | US | disclosed |
| EP-4330251-A1 | EGFR DEGRADERS AND ASSOCIATED METHODS OF USE | BeiGene Switzerland GmbH (CH) | 2024-03-06 | — | — | EP | disclosed |
| EP-4291193-A1 | EGFR DEGRADERS AND METHODS OF USE | BeiGene Switzerland GmbH (CH) | 2023-12-20 | — | — | EP | disclosed |
| CN-117222637-A | EGFR degrading agents and related methods of use | 百济神州有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2022228556-A1 | EGFR DEGRADERS AND ASSOCIATED METHODS OF USE | BEIGENE, LTD. (KY) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022171123-A1 | EGFR DEGRADERS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | GAA 1842/4885MAOA 2593/4885MAOB 2741/4885 |
| US-20260077051-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | EGFR, ERBB3, ERBB2 | GAA 3458/4885MAOA 2502/4885MAOB 2875/4885 |
| US-20240165243-A1 | EGFR DEGRADERS AND METHODS OF USE | EGFR, ERBB2, ERBB3 | GAA 1743/4885MAOA 2055/4885MAOB 2356/4885 |
| US-20240131167-A1 | EGFR Degraders and Associated Methods of Use | EGFR, ERBB2, ERBB3 | GAA 816/4885MAOA 1836/4885MAOB 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.